NoneMorgan Rogers looked to have given Unai Emery’s side another famous win when he slammed a loose ball home at the death, but referee Jesus Gil Manzano ruled Diego Carlos to have fouled Juve goalkeeper Michele Di Gregorio and the goal was chalked off. It was a disappointment for Villa, who remain unbeaten at home in their debut Champions League campaign and are still in contention to qualify automatically for the last 16. A very controversial finish at Villa Park 😲 Morgan Rogers' late goal is ruled out for a foul on Juventus goalkeeper Michele Di Gregorio and the match ends 0-0 ❌ 📺 @tntsports & @discoveryplusUK pic.twitter.com/MyYL5Vdy3r — Football on TNT Sports (@footballontnt) November 27, 2024 Emiliano Martinez had earlier displayed why he was named the best goalkeeper in the world as his wonder save kept his side level in the second half. The Argentina international paraded his two Yashin Trophies on the pitch before kick-off at Villa Park and then showed why he won back-to-back FIFA awards when he denied Francisco Conceicao. Before Rogers’ moment of drama in the fourth minute of added time, the closest Villa came to scoring was in the first half when Lucas Digne’s free-kick hit the crossbar. But a draw was a fair result which leaves Villa out of the top eight on goal difference and Juventus down in 19th. Before the game Emery called Juventus one of the “best teams in the world, historically and now”, but this was an Italian side down to the bare bones. Only 14 outfield players made the trip from Turin, with striker Dusan Vlahovic among those who stayed behind. The opening 30 minutes were forgettable before the game opened up. Ollie Watkins, still chasing his first Champions League goal, had Villa’s first presentable chance as he lashed an effort straight at Di Gregorio. Matty Cash then had a vicious effort from the resulting corner which was blocked by Federico Gatti and started a counter-attack which ended in Juventus striker Timothy Weah. Villa came closest to breaking the deadlock at the end of the first half when Digne’s 20-yard free-kick clipped the top of the crossbar and went over. Martinez then produced his brilliant save just after the hour. A corner made its way through to the far post where Conceicao was primed to head in at the far post, but Martinez sprawled himself across goal to scoop the ball away. How has he kept that one out?! 🤯 Emi Martinez with an INCREDIBLE save to keep it goalless at Villa Park ⛔️ 📺 @tntsports & @discoveryplusUK pic.twitter.com/OkcWHB7YIk — Football on TNT Sports (@footballontnt) November 27, 2024 Replays showed most of the ball went over the line, but the Argentinian got there with millimetres to spare. At the other end another fine goal-line block denied John McGinn as Manuel Locatelli got his foot in the way with Di Gregorio beaten. The game looked to be petering out until a last-gasp free-kick saw Rogers slam home, but whistle-happy official Gil Manzano halted the celebrations by ruling the goal out.
Super Micro Computer, lululemon And Roku Are Among Top 11 Large Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?Morgan Rogers looked to have given Unai Emery’s side another famous win when he slammed a loose ball home at the death, but referee Jesus Gil Manzano ruled Diego Carlos to have fouled Juve goalkeeper Michele Di Gregorio and the goal was chalked off. It was a disappointment for Villa, who remain unbeaten at home in their debut Champions League campaign and are still in contention to qualify automatically for the last 16. A very controversial finish at Villa Park 😲 Morgan Rogers' late goal is ruled out for a foul on Juventus goalkeeper Michele Di Gregorio and the match ends 0-0 ❌ 📺 @tntsports & @discoveryplusUK pic.twitter.com/MyYL5Vdy3r — Football on TNT Sports (@footballontnt) November 27, 2024 Emiliano Martinez had earlier displayed why he was named the best goalkeeper in the world as his wonder save kept his side level in the second half. The Argentina international paraded his two Yashin Trophies on the pitch before kick-off at Villa Park and then showed why he won back-to-back FIFA awards when he denied Francisco Conceicao. Before Rogers’ moment of drama in the fourth minute of added time, the closest Villa came to scoring was in the first half when Lucas Digne’s free-kick hit the crossbar. But a draw was a fair result which leaves Villa out of the top eight on goal difference and Juventus down in 19th. Before the game Emery called Juventus one of the “best teams in the world, historically and now”, but this was an Italian side down to the bare bones. Only 14 outfield players made the trip from Turin, with striker Dusan Vlahovic among those who stayed behind. The opening 30 minutes were forgettable before the game opened up. Ollie Watkins, still chasing his first Champions League goal, had Villa’s first presentable chance as he lashed an effort straight at Di Gregorio. Matty Cash then had a vicious effort from the resulting corner which was blocked by Federico Gatti and started a counter-attack which ended in Juventus striker Timothy Weah. Villa came closest to breaking the deadlock at the end of the first half when Digne’s 20-yard free-kick clipped the top of the crossbar and went over. Martinez then produced his brilliant save just after the hour. A corner made its way through to the far post where Conceicao was primed to head in at the far post, but Martinez sprawled himself across goal to scoop the ball away. How has he kept that one out?! 🤯 Emi Martinez with an INCREDIBLE save to keep it goalless at Villa Park ⛔️ 📺 @tntsports & @discoveryplusUK pic.twitter.com/OkcWHB7YIk — Football on TNT Sports (@footballontnt) November 27, 2024 Replays showed most of the ball went over the line, but the Argentinian got there with millimetres to spare. At the other end another fine goal-line block denied John McGinn as Manuel Locatelli got his foot in the way with Di Gregorio beaten. The game looked to be petering out until a last-gasp free-kick saw Rogers slam home, but whistle-happy official Gil Manzano halted the celebrations by ruling the goal out.MKs advance controversial bill to privatize or shutter Kan public broadcaster
Warren Buffett’s “Secret Stock” Revealed: Berkshire’s Surprising Bet on a Competitor and $325 Billion Cash Pile Fuels Acquisition Speculation
Lynne Roberts wasn't looking to leave as Utah women's basketball coach. Then she got a call from LAAP Business SummaryBrief at 6:02 p.m. EST
Kyle Busch had a tough time in the 2025 NASCAR Cup Series. For the first time in nearly two decades, h e failed to win a race as his historic streak came to an end. It was far from the season he expected, and it raised question marks over the 39-year-olds future. The fact he has already dipped his toe into some broadcasting work has done little to ease those fears, and he’s hinted he could step into that role eventually. "Maybe. I haven't really given it a whole lot of thought," Busch told The Athletic in October. "I'm just dipping my toe into this and giving it a shot and seeing what the networks think, what the producers think and everybody behind the scenes to see if I have a voice and an opinion later on down the road. Kyle Busch 'curse' continues even after end of disastrous NASCAR season 4 NASCAR drivers with point to prove in 2025 including Hendrick Motorsports star "I see Harvick doing it, I've seen Darrell Waltrip do it and have seen plenty of other ex-drivers go into that role. "One really good thing about that is how much you can talk up the drivers and how hard it is and about the things you love. "I've made a great living here, so you'd love to be able to give back, where some of the other guys just disappear off into the sunset and you never really hear from them again.” However, despite one eye on the future, it seems that Busch is still intent on competing, at least for the time being. He will be back with Richard Childress Racing in the No.8 car next season, and he’s got plenty of reason to continue racing. While his win streak came to an end, his season improved and he had some awful luck along the way. He lost out in two of the closest finishes in NASCAR history - at Atlanta in February then again at Daytona in August. DON'T MISS: NASCAR's own 'D.B. Cooper' disappeared without a trace after race Hamlin and Earnhardt Jr. make feelings clear on controversial NASCAR changes Chase Elliott unveils new 2025 NASCAR paint scheme after Hooters debacle On both occasions, Busch was less than 0.1 seconds from victory. He had another runner-up finish at Darlington a week after his Daytona heartbreak, and while the streak is over, he ended the season very much in the mix again. Those performances later in the regular season give him plenty of reason to believe he can get back in victory lane in 2025. Looking back at the end of a disappointing season, Busch wrote on social media: "Arguably the toughest year of my career. "Full of trials, n heartbreaks. I know my RCR guys r gonna get after it this winter n we’ll come back stronger nxt season. Grateful for all of our partners, helping us do what we love. Thx Rowdy Nation for sticking w me. Y’all r the best."MALAGA, Spain (AP) — The last man to face — and beat — Rafael Nadal in professional tennis, 80th-ranked Botic van de Zandschulp , converted his 10th match point Friday to finally close out a 6-4, 6-7 (12), 6-3 victory over Daniel Altmaier and help the Netherlands reach its first Davis Cup final by sweeping Germany. Tallon Griekspoor, who is ranked 40th, sealed the 2-0 win for the Dutch in the best-of-three-match semifinal by hitting 25 aces and coming back to defeat Jan-Lennard Struff 6-7 (4), 7-5, 6-4. When it ended, appropriately, on an ace, Griekspoor shut his eyes, dropped to his knees and spread his arms wide. “We have been talking about this for two, three years,” Griekspoor said. “We believed in ourselves so much. We always felt like this was possible. To do it now feels unbelievable.” The other semifinal is Saturday, with No. 1-ranked Jannik Sinner and defending champion Italy taking on Australia . The championship will be decided Sunday. “We don’t have that top 5 player. We don’t that top 10 player. We don’t have that top 15 player,” Dutch captain Paul Harhuuis said. “But it’s a team effort. ... So proud of these guys.” In Friday's opener, van de Zandschulp was up a set and just a point away from leading 5-2 in the second when Altmaier began playing more aggressively and interacting more with the German fans, yelling and throwing uppercuts or raising his arms after key points. In the tiebreaker, Altmaier managed to save five match points before converting his own fourth set point to extend the contest. But van de Zandschulp — who upset four-time Grand Slam champion Carlos Alcaraz at the U.S. Open — quickly moved out front in the final set, even if he eventually needed five more match points in the last game before serving it out. “At some point, I didn’t know what to do any more on the match points,” van de Zandschulp said. “I had the toughest match of my life on Tuesday (against Nadal), so everything that comes next is maybe a little bit easier.” In the quarterfinals, van de Zandschulp outplayed Nadal for a 6-4, 6-4 result that marked the end of the 22-time Grand Slam champion’s career because the Netherlands went on to eliminate Spain 2-1. The 38-year-old Nadal announced last month that the Davis Cup would be his final event before retiring. Presumably because people purchased tickets ahead of time with plans to watch Nadal compete in the semifinals, there were hundreds of unoccupied blue or gray seats surrounding the indoor hard court at the Palacio de Deportes Jose Maria Martina Carpena in southern Spain on Friday. Now truly a neutral site, the place was not nearly as loud and rowdy as on Tuesday, although there were shouts of “Vamos, Rafa!” that drew laughter while van de Zandschulp played the 88th-ranked Altmaier. It took Griekspoor more than 75 minutes and nearly two full sets to figure out how to break No. 43 Struff and then did it twice in a row — to lead 6-5 in the second set, and then go up 1-0 in the third. That was plenty, because Griekspoor saved the only two break points he faced. The Netherlands hadn’t been to the semifinals since 2001. The Germans — whose best current player, two-time major finalist Alexander Zverev, is not on the team in Malaga — have won three Davis Cups, but not since 1993, when 1991 Wimbledon champion Michael Stich led them to the title. AP tennis: https://apnews.com/hub/tennisIn 2019, Syrian President Bashar al-Assad quipped that Donald Trump was the best US President, “not because his policies are good, but because he’s the most transparent president.” In some ways, it is better to have a foe who dispenses with the pretences of human rights and democracy, and says outright: “We want the oil”, “America first”. Enough has been written about Trump’s politics since 2016, from his appeal in the deindustrialised US heartland, to his reigniting the old US political traditions of protectionism and isolationism. Rather than retread these themes, let us examine the likely policies of a second Trump administration, and the dangers and opportunities they hold for countries in the Global South. On trade policy, Trump has asked Robert Lighthizer to retake his position as US trade representative. Lighthizer is an enigmatic figure and an old school protectionist. His book No Free Trade recounts the history of US trade policy, and should be compulsory reading for any Global South policymakers who harbour illusions about free trade. Lighthizer served as a trade negotiator under Ronald Reagan, back when the chief threat to US monopolies was not Chinese but Japanese industry. Neoliberalism is often associated with austerity, trade liberalisation, and deregulation, with Ronald Reagan being one of its global faces. Yet Regan, with the help of people like Lighthizer, conducted one of the most vicious mercantilist campaigns in modern history, mobilising the full power of the state to subordinate Japanese industrialism. Neoliberalism, then, is better understood as the counterinsurgency of imperialism, rather than any specific economic policy. Imperialism is nothing but the efforts of international monopoly capital to control overseas markets and prevent the rise of competitors. Trump is transparent about it. On fiscal policy, Trump is set to continue the trend of expanding budget deficits. A report by the Committee for a Responsible Federal Budget has projected that Trump’s campaign proposals would increase the national debt by $ 7.7 trillion (nearly double the projection of Kamala Harris’ $ 3.96 trillion). US Treasury yields jumped on election day, likely due to speculation over the Federal Reserve’s ability to accommodate Trump’s fiscal plans. On monetary policy, Trump is on record stating that as President, he should, “have the right to put in comments as to whether or not the interest rate should go up and down”. During his last term as President, Trump slammed his own nominee for Federal Reserve Governor Jay Powell for not lowering interest rates fast enough. Trump’s running mate J.D. Vance has said that he has “come around to the Ron Paul argument” to abolish the Federal Reserve entirely. So, here we are. A Trump presidency will likely see rising protectionism, widening budget deficits, and an erosion of Central Bank independence. The economics textbooks at Mar-a-Lago must have been put through the shredder, incinerated, and their ashes scattered across Silicon Valley. One should not have any illusions that the Democrats would have been much different. What we are witnessing is a long-term trend. From the perspective of the Global South, the difference between the Democrats and the Republicans amounts mainly to a difference in the tempo and sequence of change. It is a rather obscene irony that Argentina’s President Javier Milei is big fan of Trump. In Argentina, Milei enforces a merciless campaign of balanced budgets and trade liberalisation. In the US, Donald Trump does the opposite. But despite these differences in domestic policies, both are united in so far as they serve imperialism; Trump in the home market, and Milei in the foreign market. The imperialist creed is, “industrial policy for me, free trade for thee”. Many in Sri Lanka, who are caught up in the hype, do not seem to realise that the theories and policies propounded by neoliberal think tanks like the Atlas Foundation-affiliated Advocata Institute and the Friedrich Naumann Foundation, have little to no influence in their own countries of origin. This particular brand of extreme economic libertarianism is exclusively an export product. When it comes to trade and industrial policy, there is more continuity than rupture between Democrats and Republicans. For an underdeveloped country like Sri Lanka, no industrial policy tool should be off the table. Yet what the ongoing IMF program has done is flip the table entirely. The debt crisis is only postponed, with the underlying problem left unsolved: a lack of industrial development, and consequently a widening trade deficit. Sri Lanka is now saddled with an independent Central Bank, an institutional feature that is conspicuously absent in all stories of late industrialisation (China’s Central Bank is still not ‘independent’). Meanwhile, the IMF expects us to open up imports by next year. Trump’s transparency opens up opportunities for industrial policy in two ways. First, Trump’s first administration threw the World Trade Organization (WTO) into disarray, and a second term will likely intensify this. There is now no need for countries like Sri Lanka to hold religiously to the WTO’s guidelines. We have a window of opportunity to experiment with trade policy in order to reduce the trade deficit and build up domestic production capacity in critical sectors like food. This will help shield against external shocks and encourage learning by doing. Second, Trump’s tariffs against China may intensify the trend of an outflow of Chinese export-oriented manufacturing investment into South East Asia, Latin America, and parts of Eastern Europe. Sri Lankan policy makers need to be actively courting value-added manufacturing investment from China, leveraging our educated workforce and the strategically located Hambantota Port which can only succeed if it produces its own traffic through manufactured exports. This will help in the acquisition of new technology, diversifying the industrial structure, and generating export revenue. One of the main challenges of a Trump presidency is the prospect of a strong and sustained rally for the US dollar. This would naturally place inflationary pressures on import-dependant countries like Sri Lanka, while driving interest rates up due to the institutionalisation of an inflation-targeting Central Bank. Most worrying is that a stronger dollar will impact Sri Lanka’s foreign debt burden, making raising revenue to repay debts much more challenging. Rising protectionism in the US, combined with China’s growing openness to the Global South, provide a window of opportunity for countries like Sri Lanka. Nothing more, nothing less. As with all opportunities, it is for us to lose. Will our leaders finally put Sri Lanka and Sri Lankans first?
Super Micro Computer, lululemon And Roku Are Among Top 11 Large Cap Gainers Last Week (Dec 2-Dec 6): Are The Others In Your Portfolio?Indian-origin man sentenced to life imprisonment for girlfriend's 'brutal' murder in UK
Kirby Smart's Blunt Admission on Transfer Portal After Earning College Football Playoff Bid
Pam Bondi, Donald Trump's pick to be attorney general, is a staunch ally of the former president, defending him against impeachment during his first term and pushing his false claims of election fraud as he sought to cling on to the White House. The 59-year-old former Florida attorney general, if confirmed by the Senate, will now serve as the top law enforcement official in a second Trump administration. "For too long, the partisan Department of Justice has been weaponized against me and other Republicans -- Not anymore," Trump wrote on his Truth Social network. "Pam will refocus the DOJ to its intended purpose of fighting Crime, and Making America Safe Again." Bondi's nomination means the top ranks of the Justice Department will be filled by Trump loyalists, as the president-elect has named three of the lawyers who defended him in his multiple criminal cases to its other high-ranking roles. Trump tapped Bondi to be attorney general on Thursday after his first pick, firebrand ex-Florida lawmaker Matt Gaetz, dropped out amid sexual misconduct allegations and doubts that he could obtain Senate confirmation. A graduate of the University of Florida with a law degree from Stetson University, Bondi served as a prosecutor for 18 years before being elected attorney general of the "Sunshine State" in 2010, the first woman to hold the post. Bondi, a native of Trump's adopted home state of Florida, was reelected to a second term in 2014. As attorney general, Bondi notably fought opioid addiction and human trafficking while taking a tough stance on crime and supporting the death penalty. She sued BP for the 2010 Deepwater Horizon oil spill in the Gulf of Mexico and obtained more than $2 billion in economic relief for Florida, according to her biography page at Ballard Partners, a powerful lobbying firm where she has worked after leaving office. While serving as attorney general, Bondi was drawn into a controversy involving Trump when she declined in 2013 to join a multi-state prosecution accusing Trump University of fraud. It emerged later that Bondi's reelection committee had received a $25,000 donation from the charitable Trump Foundation. Both Trump and Bondi denied any wrongdoing. Bondi joined Trump's legal team during his first impeachment trial, in which he was alleged to have pressured Ukrainian President Volodymyr Zelensky to find political dirt on his 2020 election opponent, Democrat Joe Biden. Trump was impeached by the Democrat-controlled House of Representatives but acquitted by the Republican-majority Senate. After the 2020 election, Bondi made television appearances on behalf of Trump and pushed to de-legitimize vote counting in battleground states as part of the push by the former president to overturn the results of the vote. Bondi has also criticized the criminal cases brought against Trump, appearing in solidarity at his New York trial, where he was convicted of falsifying business records to cover up hush money payments to a porn star. At Ballard Partners, Bondi has done work for Amazon, General Motors and Uber and as a registered lobbyist for the oil-rich Gulf nation of Qatar, according to press reports. She is also a member of the America First Policy Institute, a Trump-aligned right-wing think tank. cl/dwFeds consider additional Columbia River environmental guidelines amid political uncertainty
2025 is expected to be a transformative year for data science professionals, as the demand for skilled talent will soar across various industries. Companies are increasingly recognizing the importance of data-driven decision-making, resulting in numerous career opportunities in this dynamic field. If you aspire to advance your career in data science, this guide highlights the leading companies for data scientists and the most sought-after job positions they offer. Leading Companies in Data Science Accenture stands out in the business and consulting sector for its commitment to leveraging data science to address complex business challenges. The company provides diverse opportunities for professionals to work on AI, data engineering, and machine learning projects. This focus on innovation makes Accenture a preferred choice for those seeking career growth in data science. Deloitte is renowned for combining data science with strategic insights to drive innovation across multiple sectors. Data scientists at Deloitte work on projects ranging from financial analytics to healthcare solutions, making it a sought-after workplace for professionals eager to make an impact in varied industries. TCS, a leader in software development, offers significant Data Science Career Opportunities. The company employs data scientists to enhance its IT services and deliver AI-driven solutions for global clients. TCS’s focus on digital transformation ensures that data scientists play a critical role in shaping its offerings. IBM’s emphasis on AI and cloud technologies creates a steady demand for data scientists. IBM professionals have the chance to work on advanced projects involving machine learning, AI integration, and innovative cloud-based solutions, making it an exciting option for those looking to work at the forefront of technology. Infosys leverages data analytics to optimise business processes across industries. Its data scientists contribute to projects that drive efficiency and innovation, offering ample opportunities for growth in the field. Tech Giants and Innovation Leaders Microsoft’s heavy investment in AI and cloud computing makes it a top employer for data science professionals. Microsoft data scientists work on groundbreaking technologies that shape the future of AI-driven applications and big data analytics, ensuring exceptional career growth. Amazon’s operations in e-commerce and cloud computing rely heavily on data-driven insights. Data scientists at Amazon tackle complex challenges in logistics, customer behavior analysis, and recommendation systems. This makes Amazon a leading destination for data science talent. Oracle offers exciting roles in data science through its focus on database solutions and cloud platforms. Data scientists here work on integrating analytics and AI technologies into its services, enhancing the capabilities of its global offerings. Nvidia is at the forefront of AI and machine learning innovation. The company employs data scientists to develop hardware and software for cutting-edge deep-learning applications. Nvidia’s role in advancing AI makes it a top choice for those passionate about technological innovation. Insights into Data Science Career Opportunities The job market for data scientists is expanding rapidly, with millions of new positions expected globally by 2026. This growth is driven by the increasing adoption of AI, machine learning , and big data analytics across industries. Companies are actively seeking professionals skilled in these areas to gain a competitive edge in their respective markets. Consulting firms like Deloitte and Accenture often lead in offering high-paying roles, while tech giants such as Amazon and Microsoft provide unparalleled opportunities to work on transformative projects. A Data Science career not only offers financial rewards but also opens doors to exciting and impactful work. Why Pursue Data Science in 2025? Users require talents in analyzing data and trends, such as in IT, health care, finance, and retailing, to mention but a few. With increasing importance afforded to analytics decision-making, data scientists are strategically positioned within organisations. The field provides new directions in roles like designing and deploying AI solutions and building predictive analytical models, so the work is quite stimulating. Data science is also universal, meaning that those in the profession can secure jobs anywhere in the world. Organizations appreciate professionals who can utilize big data to increase productivity, create more value, and gain competitive advantage. Conclusion The demand for experienced data scientists is expected to remain high in 2025. Leading employers in the field, such as Accenture, Amazon, and Microsoft, will continue to recruit talent. This creates a variety of roles and excellent opportunities for career advancement, making a career in data science particularly appealing. Through ongoing personal development, aspiring data scientists can look forward to lucrative careers in this rapidly growing industry. It is now possible to secure some of the highest-paying data scientist positions and build a successful career in data science.Highway 11 to reopen after snowstorm blasted the region, stranding motoristsFort Wayne Metals Advances Capacity: Expanding Nitinol Melting Capabilities‘Infinity Nikki’ and Guys Feeling Defensive Over Enjoying “Girl Games”
Scemblix demonstrated sustained superior major molecular response (MMR) vs. all investigator-selected TKIs (74.1% vs. 52%) and vs. imatinib alone (76.2% vs. 47.1%), meeting both ASC4FIRST 96-week key secondary endpoints 1 Scemblix showed a clinically relevant 15.1% higher MMR rate vs. second generation (2G) TKIs (72.0% vs. 56.9%) 1 96-week data extend favorable safety and tolerability profile for Scemblix vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs and less than half the discontinuation rate due to AEs 1 Latest results strengthen Scemblix as a standard of care following expanded indication in newly diagnosed and previously treated adult patents with Ph+ CML-CP and NCCN category 1 recommendation 1-3 Basel, December 8, 2024 – Novartis today announced positive, longer-term results from the pivotal Phase III ASC4FIRST trial with Scemblix ® (asciminib) showing superior major molecular response (MMR) rates at week 96 1 . The study compared the MMR rate of Scemblix to investigator-selected standard-of-care (SoC) tyrosine kinase inhibitors (TKIs) (imatinib, nilotinib, dasatinib and bosutinib) and to imatinib alone in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) at the week 96 evaluation, the study’s key secondary endpoints 1 . The longer-term results showed an increasing difference in Scemblix MMR rate vs. SoC, vs. imatinib and vs. 2G TKIs (nilotinib, dasatinib and bosutinib) 1 . Results were presented at the 66 th American Society of Hematology Annual Meeting & Exposition (ASH) 1 . “These 96-week results are very encouraging for clinicians who aspire to obtain a balance of efficacy and tolerability profiles to help newly diagnosed adult CML patients achieve and maintain treatment goals,” said Jorge Cortes, M.D., Director, Georgia Cancer Center. “The sustained superior efficacy, deeper and more durable responses, and favorable safety and tolerability profile compared to standard of care TKIs continue to support the promise of Scemblix as a potentially practice-changing treatment option.” The median follow-up was 2.2 years for Scemblix and investigator-selected SoC TKIs 1 . Over 22% more patients treated with once-daily Scemblix achieved MMR at week 96 vs. all investigator-selected SoC TKIs, and nearly 30% more patients achieved MMR at week 96 vs. imatinib alone 1 . The Scemblix MMR rate was 15.1% (95% CI: 2.3, 28.0; not crossing zero) higher vs. 2G TKIs (72% vs. 56.9%) 1 . Patients treated with Scemblix also achieved deeper rates of molecular responses (MR4 and MR4.5) compared with investigator-selected SoC TKIs 1 . The safety profile of Scemblix at 96-weeks was consistent with the 4-year follow-up of the Phase III ASCEMBL trial, with no new safety concerns observed to date 1,2,4 . Fewer grade ≥3 AEs and dose adjustments to manage AEs were reported for Scemblix, and discontinuation due to AEs was more than 50% lower for Scemblix vs. both imatinib and 2G TKIs 1 . The most frequent AEs (≥15%) were diarrhea, headache, fatigue, musculoskeletal pain, and rash 1 . Novartis also presented today at ASH interim data from the Phase II ASC2ESCALATE dose-escalation study in both the second line (2L) and newly diagnosed Ph+ CML-CP settings 5 . In the analysis of 2L patients at week 24 (n=28) Scemblix demonstrated MMR rates of 42.9% and deep molecular responses (MR4 25% and MR4.5 10.7%), with a consistent safety and tolerability profile 5 . The most common AEs (>15%) were nausea, hypertension, and vomiting 5 . “Novartis’ decades-long work in CML and deep relationships within the community have informed our Scemblix clinical trial program of over 10 years, the centerpiece of our continuing drive to address ongoing unmet medical needs for people with CML,” said Jeff Legos, Executive Vice President, Global Head of Oncology Development, Novartis. “These latest findings reinforce the differentiated efficacy, safety and tolerability profile of Scemblix in newly diagnosed and previously treated adult CML patients.” Scemblix was recently granted accelerated approval in the US to treat newly diagnosed adults with Ph+ CML-CP, which together with its approval in previously treated adult patients with Ph+ CML-CP expands the population of Scemblix-eligible patients by four-fold 2 . In addition, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for the treatment of CML, recommending asciminib as a category 1 – preferred treatment for newly diagnosed Ph+ CML-CP and across all risk categories 3 . About the ASC4FIRST Phase III Clinical Trial ASC4FIRST ( NCT04971226 ) is a Phase III, head-to-head, multi-center, open-label, randomized study of oral Scemblix ® 80 mg QD vs. IS first- or second-generation TKIs (imatinib, nilotinib, dasatinib or bosutinib) in 405 adult patients with newly diagnosed Ph+ CML-CP 2,6 . The trial met both primary endpoints with Scemblix demonstrating superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%) as well as the secondary, non-powered endpoint for the 2G TKI stratum of (66% vs 57.8%) 1,6 . The study remains ongoing with further efficacy and safety readouts planned. About the ASC2ESCALATE Phase II Study ASC2ESCALATE ( NCT05384587 ) is a Phase II, multicenter, single-arm, dose-escalation study of oral Scemblix ® 80 mg QD in both the second line (2L) and newly diagnosed (1L) Ph+ CML-CP settings in the US 5,7 . While Scemblix is already approved across lines of therapy, this is the first prospective trial to assess asciminib in the 2L setting and a dose-escalation strategy of asciminib as 2L and 1L treatment for patients with CML-CP not meeting molecular milestones 5 . The proportion of patients achieving MMR at 12 months in the 2L setting will be measured as the primary endpoint 5 . The study remains ongoing and has completed enrollment with 196 patients (100 patients in 2L, 96 patients in 1L) 5 . About Scemblix ® (asciminib) Scemblix ® is the first CML treatment that works by Specifically Targeting the ABL Myristoyl Pocket (referred to as a STAMP inhibitor in scientific literature) 4,8,9 . Other currently approved CML treatments are TKIs that target the ATP-binding site (ATP-competitive) 9 . In the US, Scemblix was granted accelerated approval to treat newly diagnosed adults with Ph+ CML-CP and is also approved for previously treated adult patients with Ph+ CML-CP. Outside the US, it is approved in more than 75 countries, including the EU, to treat those who have previously been treated with two or more TKIs with Ph+ CML-CP 2,10,11 . In some countries, including the US, Scemblix is also approved in patients with Ph+ CML-CP with the T315I mutation 2,3,10 . Scemblix is being studied across multiple treatment lines for Ph+ CML-CP, both as a monotherapy and in combination 2,4,6,8,10,12-24 . Patient Access and Support Novartis, with its 20+ year history in CML, is committed to continuing to address areas of unmet patient need and reducing barriers to patient access and affordability that prevent patients from benefiting from innovation. Novartis Patient Support is available to help guide eligible patients through the various aspects of getting started on treatment including help understanding insurance coverage and identifying potential financial assistance options. Patients or providers can call 866-433-8000 or visit support.scemblix.com to learn more. About Novartis Commitment to CML Novartis has a long-standing scientific commitment to patients living with CML. For more than two decades, our bold science has helped transform CML from a life-limiting condition for many patients. Despite these advancements, there’s still work to be done. We continue to research ways to target the disease more selectively and to address the challenges of not reaching treatment efficacy goals, experiencing treatment resistance and/or intolerance that many patients face. Our legacy inspires our future innovation – we continue to lead the way in developing novel medicines to address serious unmet needs in CML. Our commitment also goes beyond science. Our 20+ year collaboration with the Max Foundation has provided access to Gleevec (imatinib), Tasigna (nilotinib) and now Scemblix and is delivering tremendous patient impact in low- and middle-income countries, with over 100,000 patients supported to date. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “may,” “committed,” “contingent,” “lead,” “continue,” “ongoing,” “to deliver,” “allowing,” “continuing,” “commitment,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Scemblix, or regarding potential future revenues from Scemblix. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Scemblix will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that Scemblix will be commercially successful in the future. In particular, our expectations regarding Scemblix could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . References Cortes JE, Hochhaus A, Hughes TP, et al. Asciminib Continues to Provide Superior Efficacy and Favorable Safety and Tolerability vs Tyrosine Kinase Inhibitors In Newly Diagnosed Chronic Myeloid Leukemia in ASC4FIRST: Week 96 Update. Presented at: 66th ASH Annual Meeting & Exposition; December 7 – 10, 2024; San Diego, CA. Scemblix (asciminib) Prescribing information. East Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation; October 2024. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Chronic Myeloid Leukemia Version 2.2025. November 13, 2024. Accessed November 22, 2024. https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf Rea D, Mauro MJ, Boquimpani C, et al. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After 2 or more prior TKIs. Blood. 2021;138(21):2031-2041. doi:10.1182/blood.2020009984 Atallah EL, Levy MY, Koller P, et al. Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI). Presented at: 66th ASH Annual Meeting & Exposition; December 7 – 10, 2024; San Diego, CA. A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP (ASC4FIRST). ClinicalTrials.gov identifier: NCT04971226. Updated March 25, 2024. Accessed March 26, 2024. https://clinicaltrials.gov/study/NCT04971226 Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (ASC2ESCALATE) ClinicalTrials.gov identifier: NCT05384587. Updated October 30, 2024. Accessed November 21, 2024. https://clinicaltrials.gov/study/NCT05384587 Cortes JE, Hughes TP, Mauro MJ, et al. Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (pts) with Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results from a Phase 1 Trial. Oral presentation at: ASH Annual Meeting; Dec. 7, 2020. Schoepfer J, Jahnke W, Berellini G, et al. Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1. J Med Chem. 2018;61(18):8120-8135. doi:10.1021/acs.jmedchem.8b01040 Novartis data on file. Scemblix. EMA Summary of Product Characteristics. Novartis Europharm Limited; 2022. Wylie AA, Schoepfer J, Jahnke W, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1. Nature. 2017;543(7647):733-737. doi:10.1038/nature21702 Hughes TP, Mauro MJ, Cortes JE, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure . N Engl J Med. 2019; 381(24):2315-2326. doi:10.1056/NEJMoa1902328 Hughes TP, et al. Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy. Presented at: ASH Annual Meeting & Exposition; Dec. 5, 2016. Ottmann OG, Alimena G, DeAngelo DJ, et al. ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy. Blood. 2015;126(23):138. doi:10.1182/blood.V126.23.138.138 Mauro MJ, Kim DW, Cortes J, et al. Combination of Asciminib Plus Nilotinib (NIL) or Dasatinib (DAS) in Patients (PTS) with Chronic Myeloid Leukemia (CML): Results from a Phase 1 Study. Presented at: EHA Annual Meeting; June 15, 2019. Cortes JE, Lang F, Kim DW, et al. Combination Therapy Using Asciminib Plus Imatinib (IMA) in Patients (PTS) with Chronic Myeloid Leukemia (CML): Results from a Phase 1 Study. Presented at: EHA Annual Meeting; June 15, 2019. Manley PW, Barys L, Cowan-Jacob SW. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase. Leuk Res. 2020;98:106458. doi:10.1016/j.leukres.2020.106458 Study of Efficacy of CML-CP Patients Treated with ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs. ClinicalTrials.gov identifier: NCT03106779. Updated February 7, 2024. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT03106779 Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and WithoutT315I Mutation (AIM4CML). ClinicalTrials.gov identifier: NCT04666259. Updated September 7, 2023. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT04666259 Study of Efficacy And Safety Of Asciminib In Combination With Imatinib In Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP). ClinicalTrials.gov identifier: NCT03578367. Updated March 22, 2024. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT03578367 Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors. ClinicalTrials.gov identifier: NCT04795427. Updated October 19, 2023. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT04795427 A Phase I Study of Oral ABL001 in Patients With CML or Ph+ ALL. ClinicalTrials.gov identifier: NCT02081378. Updated March 18, 2024. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT02081378 Asciminib Treatment Optimization in ≥ 3rd Line CML-CP. ClinicalTrials.gov identifier: NCT04948333. Updated February 28, 2024. Accessed April 3, 2024. https://clinicaltrials.gov/ct2/show/NCT04948333 # # #Socceroos striker Kusini Yengi is awaiting scan results after missing Portsmouth’s 2-2 draw with Swansea in the Championship with a knee injury. Get all the latest football news, highlights and analysis delivered straight to your inbox with Fox Sports Sportmail. Sign up now!!! Portsmouth claim Yengi suffered the injury while on international duty with Australia over the last fortnight. “He picked up an injury during the game when Australia played Bahrain,” Portsmouth manager John Mousinho said prior to his sides latest outing. It’s unclear at this stage how bad the injury is or how long Yengi will be sidelined for. The revelation comes as a slight shock given the 25-year-old played the entirety of the contest in Riffa and scored both goals, as it finished 2-2. Mousinho said Yengi picked up the injury “just before half-time.” “His knee was slightly swollen,” Mousinho added. “He was scanned on Friday afternoon. So, we’re just awaiting the final scan results and for him to see a specialist. “With knees, ankles and hips we’re always really wary.” It has been a stop-start season for the forward. He missed Pompey’s first two matches of the Championship campaign with a groin injury before being sidelined just two games into his comeback for a further five fixtures with the same complaint. Yengi had just come off a run of six games in four weeks prior to linking up with the Socceroos in Melbourne. He came on as a late substitute in a scoreless draw with Saudi Arabia in the Victorian capital before the side flew out to Bahrain. “Any injury is frustrating for us,” Mousinho said. “People do pick up injuries on international breaks. It’s probably one of the reasons why certain players don’t necessarily want to go on international duty. “We’re not one of those clubs. I want players to go away and play and represent their countries and I think it’s a really proud moment for anybody connected with Portsmouth when they do that. “It does come with a slight risk and unfortunately (Kusini) has ended up picking up an injury.” Any absence isn’t of immediate concern for the Socceroos. Tony Popovic’s side isn’t back in action until they face Indonesia and China in two must-win World Cup qualifiers in March. While Yengi has made a bright start to life for the national team, scoring six goals in 11 games, the interrupted nature of his season has impacted his output for Portsmouth. He’s yet to find the back of the net in the Championship after scoring 13-goals in 31 appearances in all competitions last season, while they were in League One, following a move from the Western Sydney Wanderers in the A-League.
Diamondback Energy Inc. stock outperforms competitors on strong trading day
College Football Playoff's first 12-team bracket is set with Oregon No. 1 and SMU in, Alabama out SMU captured the last open spot in the 12-team College Football Playoff, bumping Alabama to land in a bracket that placed undefeated Oregon at No. 1. The selection committee preferred the Mustangs, losers of a heartbreaker in the Atlantic Coast Conference title game, who had a far less difficult schedule than Alabama of the SEC but one fewer loss. The inaugural 12-team bracket marks a new era for college football, though the Alabama-SMU debate made clear there is no perfect formula. The tournament starts Dec. 20-21 with four first-round games. It concludes Jan. 20 with the national title game in Atlanta. Alabama left out of playoff as committee rewards SMU's wins over Crimson Tide's strong schedule The College Football Playoff committee took wins over strength of schedule, taking SMU over Alabama for the final at-large spot in the field. The field was expanded from four to 12 teams this season, but that didn’t save the committee from controversy. SMU showed it could compete against a traditional power, losing to Clemson 34-31 on a 56-yard field goal in the ACC title game on Saturday. Alabama had some ups and downs in its first season under coach Kalen DeBoer. The Crimson Tide had quality wins against Georgia and South Carolina, but lost at Vanderbilt, Tennessee and Oklahoma. Big Ten wins playoff selection derby, followed by SEC despite notable Alabama omission College football’s conference shakeup left concerns about two super conferences dominating the playoff field. They weren’t totally unfounded, or 100% born out. The Big Ten, not the Southeastern Conference, was the biggest winner. The ACC scored, too. The Big Ten led the initial 12-team playoff field with four making the cut, topped by a No. 1 Oregon team that was part of the Pac-12 exodus. Then came the SEC — and one notable omission. ACC runner-up SMU got the nod over college football blue-blood Alabama, another blemish in Kalen DeBoer’s first season as Nick Saban’s championship-or-bust successor. Tamar Bates scores 29 points to help Missouri beat No. 1 Kansas 76-67 COLUMBIA, Mo. (AP) — Tamar Bates had 29 points and five steals to help Missouri beat Hunter Dickinson and No. 1 Kansas 76-67. Mark Mitchell scored 17 points in Missouri’s first win over Kansas since a 74-71 victory on Feb. 4, 2012. Anthony Robinson II had 11 points and five steals for the 8-1 Tigers. Dickinson had 19 points and 14 rebounds, but he also committed seven turnovers. The 7-2 Jayhawks have lost two straight on the road after falling 76-63 against Creighton on Wednesday night. Scottie Scheffler ends his big year in the Bahamas with his 9th victory NASSAU, Bahamas (AP) — Scottie Scheffler ended his biggest year with another victory. Scheffler was coming off a two-month break and looked as good as ever. He shot 63 in the Hero World Challenge and set tournament records at Albany with a 72-hole total of 263 and a six-shot victory. Tom Kim was the runner-up and Justin Thomas finished third. Scheffler ends his year with nine victories in 21 tournaments. That includes the holiday tournament in the Bahamas and the Olympic gold medal in Paris. It's the third-highest winning percentage in the last 40 years. Tournament host Tiger Woods had two better years. Lindsey Vonn is encouraged by how close she is to being competitive in ski racing return at age 40 COPPER MOUNTAIN, Colo. (AP) — Lindsey Vonn is encouraged by how close she is to being competitive again in her ski racing return at 40 years old. Vonn is still getting her ski equipment dialed in and getting used to going full speed again on her new titanium knee. That’s why all that she's reading into being more than two seconds behind in a pair of lower-level super-G races Sunday is that she’s right there. This after nearly six years away from ski racing and an abbreviated prep period. She was 2.19 seconds behind in the first race and 2.06 in the second. Both were won by her American teammate Lauren Macuga. Plane circles MetLife Stadium with message to co-owner John Mara to fix the Giants' 'dumpster fire' EAST RUTHERFORD, N.J. (AP) — A small plane circled MetLife Stadium roughly 90 minutes before New York was to play host to the New Orleans Saints on Sunday, asking Giants co-owner John Mara to overhaul the team that has made the playoffs twice since winning the Super Bowl in February 2012. “Mr. Mara, enough. Please fix this dumpster fire!” the message read as it was towed behind the rear of a small plane. Saquon Barkley sets Eagles season rushing record and has Dickerson's NFL mark in his sights PHILADELPHIA (AP) — Saquon Barkley has broken LeSean McCoy's Eagles franchise record for rushing yards in a season. Barkley has 1,623 yards. He surpassed McCoy's mark of 1,607 yards with a 9-yard run in Sunday's 22-16 win over Carolina. Barkley finished the game with 124 yards, within a yard of his season average. He has four games left and is on pace to break Eric Dickerson's 40-year-old NFL record of 2,105 yards. Dickerson set that record in a 16-game season and Barkley has one more game. Eagles fans serenaded Barkley with “MVP!” chants and McCoy congratulated him on social media. Tua Tagovailoa's TD pass to Jonnu Smith gives Dolphins 32-26 overtime win over Aaron Rodgers, Jets MIAMI GARDENS, Fla. (AP) — Tua Tagovailoa threw a 10-yard touchdown pass to Jonnu Smith in overtime and the Miami Dolphins overcame Aaron Rodgers’ first 300-yard passing game in nearly three years to beat the New York Jets 32-26. After Jason Sanders tied it with 7 seconds left in regulation with a 42-yard field goal, Tagovailoa quickly moved the Dolphins down the field and they beat the Jets for the ninth straight time in Miami. That came after Anders Carlson gave the struggling Jets the lead with a 42-yarder with 52 seconds remaining. New York was eliminated from playoff contention for the 14th straight year. Steelers WR George Pickens to miss first game of his career with hamstring injury PITTSBURGH (AP) — Pittsburgh Steelers wide receiver George Pickens will have to wait to “introduce” himself to Cleveland Browns defensive back Greg Newsome II. Pickens is inactive for Pittsburgh's rematch against the Browns because of a hamstring injury. Newsome and Pickens ended Cleveland’s 24-19 win on Nov. 21 by tussling on Pittsburgh’s last-gasp desperation pass attempt. Pickens grabbed Newsome’s facemask as the two careened through the end zone and slammed into a restraining wall. Afterward, Newsome called the mercurial Pickens a “fake tough guy.” Pickens responded on Friday by feigning ignorance and saying he didn’t even know who Newsome was when asked if he would talk to Newsome before the game.DETROIT (AP) — Starting in September of 2027, all new passenger vehicles in the U.S. will have to sound a warning if rear-seat passengers don't buckle up. The National Highway Traffic Safety Administration said Monday that it finalized the rule, which also requires enhanced warnings when front seat belts aren't fastened. The agency estimates that the new rule will save 50 lives per year and prevent 500 injuries when fully in effect, according to a statement. The new rule will apply to passenger cars, trucks, buses except for school buses, and multipurpose vehicles weighing up to 10,000 pounds. Before the rule, seat belt warnings were required only for the driver's seat. Under the new rule, outboard front-seat passengers also must get a warning if they don't fasten their belts. Front-center seats will not get a warning because NHTSA found that it wouldn't be cost effective. The agency said most vehicles already have warnings for the outboard passenger seats. The rule also lengthens the duration of audio and visual warnings for the driver's seat. The front-seat rules are effective starting Sept. 1 of 2026. Rear passengers consistently use seat belts at a lower rate than front passengers, the agency says. In 2022, front belt use was just under 92%, while rear use dropped to about 82%. About half of automobile passengers who died in crashes two years ago weren’t wearing belts, according to NHTSA data. The seat belt rule is the second significant regulation to come from NHTSA in the past two months. In November the agency bolstered its five-star auto safety ratings to include driver assistance technologies and pedestrian protection. Safety advocates want the Department of Transportation, which includes NHTSA, to finish several more rules before the end of the Biden administration, because President-elect Donald Trump has said he’s against new government regulations. Cathy Chase, president of Advocates for Highway and Auto Safety, urged the department to approve automatic emergency braking for heavy trucks and technology to prevent impaired driving.